Phosphodiesterase‑4 inhibitors: a review of current developments (2013-2021).

Zhihao Liu, Mingjian Liu, Zhenqing Cao, Pengsen Qiu, Gaopeng Song

Expert opinion on therapeutic patents 2022 Mar

filter terms:

Cyclic nucleotide phosphodiesterase 4 (PDE4) is responsible for the hydrolysis of cAMP, which has become an attractive therapeutic target for lung, skin, and severe neurological diseases. Here, we review the current status of development of PDE4 inhibitors since 2013 and discuss the applicability of novel medicinal-chemistry strategies for identifying more efficient and safer inhibitors. This review summarizes the clinical development of PDE4 inhibitors from 2013 to 2021, focused on their pharmacophores, the strategies to reduce the side effects of PDE4 inhibitors and the development of subfamily selective PDE4 inhibitors. To date, great efforts have been made in the development of PDE4 inhibitors, and researchers have established a comprehensive preclinical database and collected some promising data from clinical trials. Although four small-molecule PDE4 inhibitors have been approved by FDA for the treatment of human diseases up to now, further development of other reported PDE4 inhibitors with strong potency has been hampered due to the occurrence of severe side effects. There are currently three main strategies for overcoming the dose limitation and systemic side effects, which provide new opportunities for the clinical development of new PDE4 inhibitors.

Citation

Zhihao Liu, Mingjian Liu, Zhenqing Cao, Pengsen Qiu, Gaopeng Song. Phosphodiesterase‑4 inhibitors: a review of current developments (2013-2021). Expert opinion on therapeutic patents. 2022 Mar;32(3):261-278